Amarin Corp Plc (AMRN)

[ziploc_1]

The November 14 "tentative" date will give Amarin more time to lay the foundations for a vigorous presentation of the benefits of Vascepa...They will point to the numerous meetings, both in the U.S. and in Europe that have extolled Vascepa...the societies, also both in the U.S. and in Europe, which have endorsed Vascepa as a treatment for CVD, even to go as far as to make Vascepa a SOC in diabetics at cardiovascular risk...They will reiterate the details of R-IT, which generated reductions in CVE, even in patients with normal Triglycerides... they will introduce testimonies from patients and from medical researchers, who are cardiologists and KOLS...The FDA will also have time to prepare...I can't wait to personally be present at the Adcom to see what contributions the panel can further make.